Methods for diagnosing alzheimer's disease
AssigneeWashington University
InventorsDavid Holtzman, Randall Bateman
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for Aβ amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.
Claims21
A method of diagnosing or monitoring the progression or treatment of Aβ amyloidosis in a subject, the method comprising measuring the in vivo relative labeling of Aβ variants, including Aβ38, Aβ40 or Aβ42 in a biological sample from the subject, and calculating the ratio of relative labeling of the Aβ42 protein variant to the relative labeling of another Aβ protein variant, wherein a ratio other than 1 indicates the presence of Aβ amyloidosis.
The method of claim 13, wherein the non-radioactive isotope is selected from the group consisting of 2H, 13C, 15N, 17O, 18O, 33S, 34S, and 36S.
A method of diagnosing or monitoring the progression or treatment of Aβ amyloidosis in a subject, the method comprising measuring the in vivo relative labeling of an Aβ variant, including Aβ38, Aβ40 or Aβ42 in a biological sample from the subject, and comparing the labeling to a control sample, wherein a difference in amount of label indicates the presence of Aβ amyloidosis.
Dependencies are inferred from the claim text.